American Heart Association (AHA) Scientific Sessions 2020 - A Virtual Experience

13 November 2020 - 17 November 2020

Pre-/post-discharge sotagliflozin may reduce CV death, hospitalization in T2D patients with HF

28 Jan 2021 by

Sotagliflozin given pre- or shortly post-discharge to patients with type 2 diabetes (T2D) recently hospitalized for worsening heart failure (HF) may result in a reduced risk of cardiovascular (CV) death, hospitalization, or urgent visits for HF, according to results of the phase III SOLOIST-WHF* trial.

Pre-/post-discharge sotagliflozin may reduce CV death, hospitalization in T2D patients with HF

28 Jan 2021

Polypill + aspirin TIPped as CVD primary prevention strategy

14 Jan 2021 by

A single polypill combining a beta blocker, ACE* inhibitor, statin, and diuretic, in addition to a daily dose of aspirin, significantly reduced the risk of cardiovascular disease (CVD) in patients with intermediate CV risk, according to the TIPS**-3 study presented at the AHA 2020 Scientific Sessions.

Polypill + aspirin TIPped as CVD primary prevention strategy

14 Jan 2021

High-dose flu vaccine no better than standard-dose in reducing death, CV hospitalization

21 Dec 2020 by

Patients with high cardiovascular (CV) risk who received a high-dose trivalent influenza vaccine over three influenza seasons did not have a lower risk of cardiopulmonary hospitalization or death compared with those who received a standard-dose quadrivalent vaccine, according to the INVESTED* trial presented at AHA 2020.

High-dose flu vaccine no better than standard-dose in reducing death, CV hospitalization

21 Dec 2020

Rilonacept shows therapeutic potential for recurrent pericarditis

21 Dec 2020 by

In patients with recurrent pericarditis (RP), the interleukin (IL)-1α and IL-1β cytokine trap rilonacept significantly reduced the risk of recurrence, with rapid resolution of episodes, the RHAPSODY* trial has shown.

Rilonacept shows therapeutic potential for recurrent pericarditis

21 Dec 2020

Obesity portends worse outcomes in COVID-19, even for young adults

18 Dec 2020 by

Obesity, particularly the severe class, was associated with an increased risk of mechanical ventilation and death in patients hospitalized with COVID-19 — a risk that is even more profound among the younger age group, reveals data from the AHA COVID-19 CVD registry*.

Obesity portends worse outcomes in COVID-19, even for young adults

18 Dec 2020

Omecamtiv mecarbil: New player in HF treatment?

18 Dec 2020 by

Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.

Omecamtiv mecarbil: New player in HF treatment?

18 Dec 2020

AFFIRM-AHF: IV iron cuts risk of HF readmissions

15 Dec 2020 by

Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.

AFFIRM-AHF: IV iron cuts risk of HF readmissions

15 Dec 2020

Finerenone lowers CV risk in patients with CKD, T2D

12 Dec 2020 by

Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.

Finerenone lowers CV risk in patients with CKD, T2D

12 Dec 2020